

S4 Table. Excluded 63 studies of radiotherapy alone or upfront chemoradiotherapy [1-63]

-
1. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. *Ann Surg.* 1979;189:205-8.
 2. Azria D, Ychou M, Jacot W, Thezenas S, Lemanski C, Senesse P, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. *Pancreas.* 2002;25:360-5.
 3. Bajetta E, Di Bartolomeo M, Stani SC, Artale S, Ricci SB, Bozzetti F, et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. *Int J Radiat Oncol Biol Phys.* 1999;45:285-9.
 4. Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schonemann KR, et al. Long-term results of concurrent radiotherapy and UFT in patients with locally advanced pancreatic cancer. *Radiother Oncol.* 2009;92:226-30.
 5. Blackstock AW, Tepper JE, Niedwiecki D, Hollis DR, Mayer RJ, Tempero MA. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. *Int J Gastrointest Cancer.* 2003;34:107-16.
 6. Brunner TB, Grabenbauer GG, Kastl S, Herrmann O, Baum U, Fietkau R, et al. Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. *Onkologie.* 2000;23:436-42.
 7. Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. *Am J Clin Oncol.* 2011;34:460-5.
 8. Cengiz M, Zorlu F, Yalcin S, Gurkaynak M, Atahan IL, Gullu IH. Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. *Med Oncol.* 2007;24:239-43.
 9. Chung HW, Bang SM, Park SW, Chung JB, Kang JK, Kim JW, et al. A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2004;60:1494-501.
 10. Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. *Int J Radiat Oncol Biol Phys.* 2005;62:1345-50.
 11. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. *Int J Pancreatol.* 2001;29:9-18.
 12. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411. *J Clin Oncol.* 2009;27:4096-102.
 13. de Lange SM, van Groeningen CJ, Meijer OW, Cuesta MA, Langendijk JA, van Riel JM, et al. Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer. *Eur J Cancer.* 2002;38:1212-7.
 14. Ducreux M, Giovannini M, Baey C, Llacer C, Bennouna J, Adenis A, et al. Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial. *Dig Liver Dis.* 2014;46:950-5.
 15. Earle JD, Foley JF, Wieand HS, Kvols LK, McKenna PJ, Krook JE, et al.
-

Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 1994;28:207-11.

16. Fiore M, Trodella L, Valeri S, Borzomati D, Floreno B, Ippolito E, et al. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. *Radiat Oncol.* 2015;10:255.
 17. Haddock MG, Swaminathan R, Foster NR, Hauge MD, Martenson JA, Camoriano JK, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. *J Clin Oncol.* 2007;25:2567-72.
 18. Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, et al. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. *J Clin Oncol.* 2013;31:886-94.
 19. Hong SP, Park JY, Jeon TJ, Bang S, Park SW, Chung JB, et al. Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. *Br J Cancer.* 2008;98:881-7.
 20. Hoyer M, Roed H, Sengelov L, Traberg A, Ohlhuis L, Pedersen J, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. *Radiation Oncol.* 2005;76:48-53.
 21. Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, et al. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2012;83:921-6.
 22. Ikeda M, Ioka T, Ito Y, Yonemoto N, Nagase M, Yamao K, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2013;85:163-9.
 23. Ishii H, Okada S, Tokuyue K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. *Cancer.* 1997;79:1516-20.
 24. Jackson AS, Jain P, Watkins GR, Whitfield GA, Green MM, Valle J, et al. Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. *Clin Oncol (R Coll Radiol).* 2010;22:570-7.
 25. Jensen EH, Armstrong L, Lee C, Tuttle TM, Vickers SM, Sielaff T, et al. Neoadjuvant interferon-based chemoradiation for borderline resectable and locally advanced pancreas cancer: a Phase II pilot study. *HPB (Oxford).* 2014;16:131-9.
 26. Jessup JM, Steele G, Jr., Mayer RJ, Posner M, Busse P, Cady B, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. *Arch Surg.* 1993;128:559-64.
 27. Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. *Cancer Chemother Pharmacol.* 2009;63:535-41.
 28. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys.* 2005;63:320-3.
 29. Kornek GV, Potter R, Selzer E, Schratte A, Ulrich-Pur H, Rogy M, et al. Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine. *Int J Radiat Oncol Biol Phys.* 2001;49:665-71.
 30. Kornek GV, Schratte-Sehn A, Marczell A, Depisch D, Karner J, Krauss G, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined
-

radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. *Br J Cancer*. 2000;82:98-103.

31. Li CP, Chao Y, Chi KH, Chan WK, Teng HC, Lee RC, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. *Int J Radiat Oncol Biol Phys*. 2003;57:98-104.
 32. Magnino A, Gatti M, Massucco P, Sperti E, Faggiuolo R, Regge D, et al. Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer. *Oncology*. 2005;68:493-9.
 33. Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, et al. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. *Cancer*. 2011;117:2620-8.
 34. Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. *Ann Surg Oncol*. 2006;13:1201-8.
 35. Mattiucci GC, Morganti AG, Valentini V, Ippolito E, Alfieri S, Antinori A, et al. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. *Int J Radiat Oncol Biol Phys*. 2010;76:831-8.
 36. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. *Cancer*. 1981;48:1705-10.
 37. Morak MJ, Richel DJ, van Eijck CH, Nuyttens JJ, van der Gaast A, Vervenne WL, et al. Phase II trial of Uracil/Tegafur plus leucovorin and celecoxib combined with radiotherapy in locally advanced pancreatic cancer. *Radiother Oncol*. 2011;98:261-4.
 38. Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F, et al. 5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: Phase I-II dose-escalation study. *Int J Radiat Oncol Biol Phys*. 2004;59:1454-60.
 39. Nguyen TD, Theobald S, Rougier P, Ducreux M, Lusinchi A, Bardet E, et al. Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study. *Radiother Oncol*. 1997;45:129-32.
 40. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. *Br J Cancer*. 2004;91:673-7.
 41. Okusaka T, Okada S, Tokuyue K, Wakasugi H, Saisho H, Ishikawa O, et al. Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. *Cancer*. 2001;91:1384-9.
 42. Osti MF, Costa AM, Bianciardi F, De Nicolo M, Donato V, Silecchia G, et al. Concomitant radiotherapy with protracted 5-fluorouracil infusion in locally advanced carcinoma of the pancreas: a phase II study. *Tumori*. 2001;87:398-401.
 43. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, et al. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. *Ann Surg Oncol*. 2010;17:2092-101.
 44. Prott FJ, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O, et al. Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
-

Br J Cancer. 1997;75:597-601.

45. Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, et al. Phase II trial of cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. *Transl Oncol*. 2014;7:55-64.
 46. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. *Am J Clin Oncol*. 2004;27:51-6.
 47. Rich TA, Winter K, Safran H, Hoffman JP, Erickson B, Anne PR, et al. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. *Onco Targets Ther*. 2012;5:161-70.
 48. Safran H, Moore T, Iannitti D, Dipetrillo T, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2001;49:1275-9.
 49. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2011;81:181-8.
 50. Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y, et al. Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer. *Am J Clin Oncol*. 2011;34:115-9.
 51. Shinchi H, Maemura K, Mataka Y, Kurahara H, Sakoda M, Ueno S, et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. *J Hepatobiliary Pancreat Sci*. 2012;19:152-8.
 52. Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Hara T, Denda T, et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2011;80:119-25.
 53. Thomas CR Jr, Weiden PL, Traverso LW, Thompson T. Concomitant intraarterial cisplatin, intravenous 5-fluorouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703). *Am J Clin Oncol*. 1997;20:161-5.
 54. Tokuyue K, Sumi M, Kagami Y, Murayama S, Ikeda H, Ikeda M, et al. Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. *Radiother Oncol*. 2003;67:327-30.
 55. Turrini O, Viret F, Moureau-Zabotto L, Guiramand J, Moutardier V, Lelong B, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. *Eur J Surg Oncol*. 2009;35:1306-11.
 56. Wilkowski R, Boeck S, Ostermaier S, Sauer R, Herbst M, Fietkau R, et al. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study. *Br J Cancer*. 2009;101:1853-9.
 57. Maximous D, Abdel-Wanis ME, Aboziada MA, El-Sayed MI, Abd-Elsayed AA. Preoperative gemcitabine based chemoradiotherapy in locally advanced nonmetastatic pancreatic adenocarcinoma. *J Clin Oncol*. 2009;27(15S):e15677.
 58. Shinchi H, Takao S, Noma H, Matsuo Y, Mataka Y, Mori S, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. *Int J Radiat Oncol Biol Phys*. 2002;53:146-50.
 59. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of
-

combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma: an outcomes trial. *Cancer*. 2000;89:314-27.

60. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. *JOP*. 2006;7:349-60.

61. Kim YJ, Lee WJ, Woo SM, Kim TH, Han SS, Kim BH, et al. Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. *Radiat Oncol*. 2013;8:160.

62. Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. *Cancer*. 1985;56:2563-8.

63. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. *World J Surg*. 2004;28:1011-8.
